Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 3, 2007, Pages 407-413

  Bourgeois, H ^a   Vermorken, J ^b   Dark, G ^c   Jones, A ^d   Fumoleau, P ^e   Stupp, R ^f   Tourani, J ^a   Brain, E ^g   Nguyen, L ^h   Lefresne, F ^h   Puozzo, C ^h  

^a University of Poitiers   (France)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f Service d'Angiologie Hôpital Universitaire   (Switzerland)

^g CENTRE RENÉ HUGUENIN   (France)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BREAST CARCINOMA; BREAST METASTASIS; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG CARCINOMA; LUNG METASTASIS; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; VINBLASTINE;

EID: 34250617954     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0510-z     Document Type: Article

References (18)

1. Bonneterre J, Chevalier B, Focan C, Mauriac L, Piccart M (2001) Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12(12):1683-1691
2. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38(3):349-358
3. Bugat R, Variol P, Roché H, Fumoleau P, Robinet G, Sénac I (2002) The effect of food on pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 50:285-290
4. CPMP Working party on efficacy of medicinal products (Dec1991) Note for guidance: investigation of bioavailability and bioequivalence. III/54/89-EN
5. Crawford J, O'Rourke M, Schiller JH et al (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV NSCLC. J Clin Oncol 14(10):2774-2784
6. Depierre A, Chastang Cl, Quoix E, Lebeau B, Blanchon F, et al (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann Oncol 5:37-42
7. Diletti E, Hauschke D, Steinnijans VW (1991) Sample size determination for bioequivalence assessment by mean of confidence intervals. Int J Clin Pharmacol Ther 30(1):S51-S58
8. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 19:3210-321
9. Khayat D, Rixe O, Dr Brunet, Dr Goupil, Bugat R, Harousseau JL, Dr Ifrah, Puozzo C (2004) Pharmacokinetic linearity of IV vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54(3):193-205
10. Le Chevalier T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplating versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367
11. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110-115
12. Lush RM, McCune JS, Tetteh L, Thompson JA, Mahany JJ, Garland L, Suttle AB, Sullivan DM (2005) The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 56(6):578-584
13. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649
14. Nguyen L, Tranchant B, Puozzo C, Variol P (2002) Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53:459-468
15. Puozzo C (2006) Can similar oral blood exposures between studies result in a different bioavailability? Cancer Chemother Pharmacol 58:838-841
16. Ramlau R, Hausen O, Wagner L et al (2003) A full Navelbine oral treatment in combination with cisplatin followed by NVB oral single agent as consolidation therapy in NSCLC. Eur J Cancer S247 (abst. 823)
17. Van Heugen JC, De Graeve J, Zorza G, Puozzo C (2001) New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr 926:11-20
18. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin versus cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16(7):2459-2465